Track Record

Powering Successes Since 2002

With a portfolio of 350+ companies across the health IT, medical device and bio-pharmaceutical sectors, BioEnterprise has generated XXX in investment and XXX in returns since XXXX.

With an entirely healthcare-focused team of executives-in-residence and other advisors, BioEnterprise helps startups uncover new sources of growth capital, access top talent, create effective business strategy and forge new partnerships. Through a shared vision with partner institutions, including Cleveland Clinic, University Hospitals, Case Western Reserve University and The MetroHealth System, BioEnterprise is expanding the region’s bioscience industry, creating regional jobs and making Cleveland a national leader in healthcare innovation.



Estimated value of the Northeast Ohio bioscience community


Northeast Ohio's healthcare GDP; up 37% since 2001


Biotech, HIT, and medical device businesses in NEO


Bioscience exits in Northeast Ohio since 2002, totalling $11B, not including deals with undisclosed terms


Active investors in Northeast Ohio bioscience companies



First tenant of the BioEnterprise Incubator in 2002, where it developed a pharmaceutical stem cell therapy called MultiStem to treat diseases and conditions in the neurological, inflammatory and immune, and cardiovascular areas. Now a $255M company that went public in 2007.

Convelo Therapeutics

Developer of regenerative medicines to treat multiple sclerosis. Raised $13M in growth capital since 2017 with on-loan BioEnterprise employees to fuel growth. In 2019, entered strategic partnership with Genentech with an option to acquire.


Drug development acceleration partner to UH Harrington Discovery Institute within Harrington Project for Discovery and Development. Launched at BioEnterprise Incubator, with $145M in growth capital raised to date and a recently announced partnership with pharmaceutical giant Bristol-Myers Squibb.


Invented a non-invasive mapping technology for electrical disorders of the heart in 2004, commercialized by CWRU researchers. Raised $37M in growth capital before being acquired by Medtronic in 2015.